Topical peptide serums for skin: separating hype from evidence

What did @drheatherrogers actually say?

Dr. Heather Rogers, a board-certified dermatologist, pushed back against peptide serums in a TikTok reply. Her core position: peptides are not a "level A ingredient" alongside vitamin C, sunscreen, or retinoids. She acknowledged they "can activate positive changes" but warned they can also irritate skin and that using them means "asking more of your skin" in ways that may cause problems. She didn't say never use them. She said don't prioritize them over the basics.

This is a measured, clinical take, not a fear-mongering one. She's drawing a hierarchy of evidence, not condemning a category. That distinction matters when you're reading her claims charitably and critically at the same time.

Does the science back this up?

Mostly, yes. The evidence for topical peptides is real but limited, and the hierarchy she describes is defensible based on the literature.

Sunscreen and broad-spectrum UV protection have decades of randomized controlled trial data behind them. Vitamin C (L-ascorbic acid) has solid mechanistic and clinical evidence for photoprotection and collagen synthesis support (Pinnell et al., 2001, Dermatologic Surgery). Retinoids remain the most studied topical anti-aging compound in dermatology, with strong evidence going back to Kligman's work in the 1980s.

Topical peptides? The data exists but is thinner. A 2009 review by Gorouhi and Maibach in the International Journal of Cosmetic Science found that while certain peptides, particularly signal peptides like palmitoyl pentapeptide-4 (Matrixyl), showed promising results for collagen stimulation, most studies were small, industry-funded, and lacked independent replication. A 2021 review in the Journal of Cosmetic Dermatology by Schagen confirmed biological plausibility for several peptide classes but noted that concentration, formulation stability, and skin penetration remain significant variables. So Rogers is right that the evidence base is weaker compared to retinoids and vitamin C.

What did they get wrong (or right)?

She got the hierarchy right. Where she gets imprecise is the irritation claim.

Her statement that peptides "can irritate your skin" because they make skin "turn over quickly" and "build collagen" conflates two different mechanisms. Most topical peptides do not cause the kind of cellular turnover that produces irritation. That's retinoid territory. Peptide irritation, when it occurs, is more likely from vehicle ingredients, preservatives, or destabilized formulations than from the peptides themselves. Pure peptide molecules are generally well-tolerated in clinical settings.

Signal peptides like palmitoyl tripeptide-1 work by mimicking collagen breakdown fragments to stimulate fibroblast activity. They don't accelerate surface cell turnover the way tretinoin does. Rogers may be describing a real clinical pattern she observes, but the mechanism she implies doesn't hold up cleanly under scrutiny.

To her credit, she's right that peptide complexity is a legitimate problem. With hundreds of peptide variants marketed under confusing names, even dermatologists struggle to evaluate claims. That's an honest and useful admission.

What should you actually know?

Topical peptides are not snake oil, but they're also not the foundation of a skincare routine. The evidence supports their use as add-ons for specific goals like collagen support or barrier repair, not replacements for established actives.

If you're building a routine from scratch, Rogers' hierarchy is reasonable: broad-spectrum SPF daily, a vitamin C serum if you tolerate it, a moisturizer appropriate for your skin type, and a retinoid if your skin can handle it. Peptides fit after those boxes are checked.

One area where topical peptides do have stronger evidence is barrier repair. Peptides like GHK-Cu (copper peptide) have shown meaningful wound-healing and anti-inflammatory properties in multiple studies, including work by Pickart and Margolina (2018, Biomolecules). If your concern is sensitive or compromised skin rather than anti-aging, the use case changes.

Finally, "peptides" is not one thing. Neurotransmitter-inhibiting peptides (like Argireline), carrier peptides (like copper peptide), and signal peptides (like Matrixyl) work through completely different pathways. Treating them as a single category, as most marketing does, is where real confusion begins.